جست‌وجوی استاد و پژوهشگر

Shengwu Liمشاهده پروفایل

استاد

• Behavioral Economics
• Oncology
• Molecular Biology
• +۳ مورد دیگر

Shengwu Li is a Professor of Economics at Harvard University’s Department of Economics, affiliated with the Faculty of Arts and Sciences (FAS). He previously served as a Junior Fellow of the Society of Fellows. His research spans behavioral economics theory and molecular oncology, focusing on mechanisms of cancer drug resistance, targeted therapies, and epigenetic regulation in tumors. He has contributed to understanding KRAS inhibition resistance, HER2 exon 20 insertion mutations, and synergistic immunotherapies combining epigenetic modifiers with immune checkpoint blockade. Education details not explicitly listed in the text. Research interests include behavioral economic models of decision-making under uncertainty, coupled with experimental studies in cancer biology. His work bridges theoretical economics and translational oncology, addressing challenges in precision medicine and drug development. Recent studies explore therapeutic efficacy of CDK7 inhibitors in pancreatic cancer and mechanisms of adeno-to-squamous transition in lung tumors. Notable achievements include the Junior Fellow distinction, highlighting early-career excellence in interdisciplinary research. Collaborative projects involve preclinical models of tumor organoids and ex vivo patient-derived spheroids to identify combination therapies for HER2-mutant lung cancers.

Ludger Kleinمشاهده پروفایل

استاد

• Immunology
• T Cell Development
• Central Tolerance
• +۲ مورد دیگر

Ludger Klein is a Professor at the Ludwig-Maximilians-Universität München (LMU Munich) and leads the Department of Immunology . He serves as Group Leader and Scientific Manager of the Flow Cytometry Facility at the Biomedical Center Munich. T cell Development Central Tolerance Regulatory T Cells T Cell Repertoire Analyses His research focuses on understanding how the thymic microenvironment orchestrates T cell fate decisions, particularly through mechanisms like deletion of self-reactive T cells and induction of regulatory T cells. Recent publications highlight studies on T cell receptor dynamics, MHCII regulation in cortical epithelial cells, and the role of thymic B cells in antigen presentation for tolerance induction. Key collaborators and advisees include doctoral researchers like Joao Teixeira de Freitas , Madlen Steinert , and Chunyan Wu , as well as former PhD students such as Tobias Haßler and Julia von Rohrscheidt . Ludger Klein's lab is based at the Biomedical Center Munich, with expertise in flow cytometry and immune tolerance mechanisms. The group has published extensively on T cell biology and autoimmune disease prevention.

Ramana V Davuluriمشاهده پروفایل

استاد

• Machine Learning
• Cancer Data Science
• Gene Regulation
• +۴ مورد دیگر

Ramana V Davuluri serves as Professor in the Department of Biomedical Informatics at Stony Brook University's Renaissance School of Medicine. With over 20 years of experience in bioinformatics and computational genomics, he leads research at the intersection of machine learning and cancer genomics, focusing on translating high-dimensional -omic data into clinically actionable insights through statistically rigorous methodologies. Dr. Davuluri's research spans Machine Learning applications in Cancer Data Science , isoform-level gene regulation , and precision-medicine development. His lab pioneers bioinformatics solutions for genomic data interpretation, with emphasis on developing machine learning algorithms that convert NextGen sequencing outputs into experimentally testable discovery models. A core focus involves creating rapid biomarker identification systems from human tissue and blood samples through integrated computational-experimental approaches in systems biology. Analysis of his 2023-2025 publications reveals a dominant trend toward genomic foundation models (e.g., DNABERT variants), multi-omic cancer subtyping , and time-dependent therapeutic strategies for pediatric brain tumors and ovarian cancer. His work consistently bridges computational innovation with biological validation across diverse cancer types including glioma, lung adenocarcinoma, and high-grade serous carcinoma. As Principal Investigator for multiple multi-investigator and multi-site projects, Dr. Davuluri directs research integrating high-throughput experimental procedures with advanced data-mining techniques. His laboratory maintains strong collaborations across oncology, neuroscience, and immunology domains while developing genomics-based decision support systems for clinical translation. The Davuluri Lab employs a systems biology framework to develop novel informatics tools for precision oncology, with particular emphasis on translating genomic discoveries into clinical applications through biomarker discovery and therapeutic strategy optimization.

Arnoldo Frigessiمشاهده پروفایل

استاد

• Statistics
• Biostatistics
• Machine Learning
• +۵ مورد دیگر

Arnoldo Frigessi is Professor of Statistics at the University of Oslo, where he leads the Oslo Center for Biostatistics and Epidemiology and serves as director of BigInsight—a Centre of Excellence for Research-Based Innovation. This consortium unites industry, business, public actors, and academia to develop model-based machine learning methodologies for big data, with strong emphasis on health applications. His research centers on statistical methodology driven by real-world scientific challenges, specializing in stochastic models for complex dependence structures and computationally intensive inference algorithms. Core application domains include: Genomics and personalized cancer therapy (particularly breast and lung cancer) Infectious disease modeling (including pandemic response) eHealth, sensor data analysis, and recommender systems Personalized marketing and viral diffusion dynamics Analysis of his 15 most recent publications (2024-2025) reveals dominant themes in cancer systems biology , where he integrates multi-omics, single-cell transcriptomics, and computational modeling to decode tumor evolution under therapy. Parallel work advances infectious disease epidemiology through time-varying reproduction number estimation and mobility-based transmission modeling, while methodological innovations span synthetic data generation (TVineSynth), causal inference via target trial emulation, and Bayesian ranking models for recommender systems. Scientific Awards: No specific awards mentioned in source materials Frigessi actively supervises graduate students, including a Department of Informatics project on "Utilizing covariate information in recommender systems." His leadership of BigInsight—funded as a Research-Based Innovation Centre by the Research Council of Norway—secures major grants supporting interdisciplinary collaborations with industrial partners (e.g., Telenor, DNB) and public health institutions. Current projects integrate real-world clinical data with mechanistic models for treatment optimization. He directs BigInsight's multidisciplinary team of statisticians, computer scientists, and domain experts, while leading the Oslo Center for Biostatistics and Epidemiology's efforts in developing statistical frameworks for complex health data. These initiatives drive Norway's national strategy for data-driven health innovation.

Antonia Beitzen-Heinekeمشاهده پروفایل

مدرس پزشکی

• Oncology
• Hematology
• Hemostaseology
• +۴ مورد دیگر

Antonia Beitzen-Heineke is a Medical Specialist in Internal Medicine, Hematology, and Oncology at the University Medical Center Hamburg-Eppendorf (UKE). She holds dual affiliations in the II. Medical Clinic and Polyclinic (Center for Oncology) and the Institute of Tumor Biology within the Center for Experimental Medicine. Her expertise spans oncology, hematology, and hemostaseology , with a focus on cardio-oncology, chemotherapy-induced toxicity, and coagulation disorders in cancer patients. Her research emphasizes translational studies in tumor biology, including the molecular mechanisms of coagulation activation in acute myeloid leukemia and the role of AXL inhibition in myeloproliferative neoplasms. She also investigates long-term cardiovascular effects of cancer therapies, leveraging cardiac MRI for early detection of myocardial dysfunction. Publications highlight her work on thrombosis in paroxysmal nocturnal hemoglobinuria, checkpoint inhibitor immunotherapy’s impact on hemostasis, and athlete cardiac adaptations. She collaborates with multidisciplinary teams in radiology, immunology, and pharmacology. Her clinical roles involve managing patients with hematologic malignancies and complex coagulation pathologies. No scientific awards are explicitly noted, but her active research profile underscores contributions to cardio-oncology and thrombosis biology.

Ellen Robeyمشاهده پروفایل

استاد

• Immunology
• Molecular Biology
• Cell Biology
• +۳ مورد دیگر

Ellen Robey is a Professor of Immunology and Molecular Medicine at the University of California, Berkeley, serving as Division Head of the IMM Division. Her research focuses on signaling pathways controlling T cell fate decisions, using mouse models to study T cell development and immune responses, including mechanisms of thymic selection and CD4/CD8 lineage commitment. She employs 2-photon imaging to analyze T cell behavior in situ, particularly during parasitic infections like Toxoplasma gondii . Robey’s lab investigates how self-reactivity influences thymic selection timing and develops collaborative projects combining multi-omics approaches with spatial and temporal analyses of thymic development. Key research areas include understanding negative/positive selection mechanisms in the thymus, immune response dynamics during chronic infections, and the role of unconventional T cell subsets recognizing non-classical MHC molecules. The lab has pioneered studies on Qa1-restricted T cells and their role in host defense against pathogens. Her work bridges basic immunology with cutting-edge imaging and systems biology tools to unravel complex immune processes. Lab collaborations include projects with Nir Yosef and Aaron Streets to create high-resolution thymic developmental maps using single-cell multi-omics. Current efforts also explore how ERAAP downregulation alters antigen presentation, influencing T cell responses. The Robey Lab emphasizes diversity in its team, fostering an inclusive environment for scientific innovation.

• Genome Stability
• DNA Repair Mechanisms
• Cancer Biology
• +۳ مورد دیگر

J. Ross Chapman is a Professor of Genome Maintenance Biology at the University of Oxford, affiliated with the MRC Molecular Haematology Unit. He holds fellowships from Cancer Research UK and the Lister Institute, and is part of the EMBO Young Investigator Programme. His research focuses on DNA repair mechanisms, particularly the balance between accurate and mutagenic repair pathways in cancer and immune disorders. Career highlights include roles as a Sir Henry Wellcome Fellow and Principal Investigator. His group studies genetic recombination mechanisms, aiming to develop cancer therapies targeting repair pathway dysfunctions. Key research areas include the role of BRCA1, BARD1, 53BP1, and CST complexes in DNA repair. Awards include CRUK and Lister Institute Fellowships, alongside EMBO recognition. His lab’s work spans genomic stability, immune system development, and cancer therapy strategies. Recent studies explore chronic inflammation in leukemia evolution and synthetic lethality in BRCA-deficient cells.

• Biostatistics
• Oncology
• Hematology
• +۳ مورد دیگر

Andrea M. Baran, M.S. serves as a Senior Associate (Part-Time) in the Department of Biostatistics and Computational Biology at the University of Rochester School of Medicine and Dentistry. With expertise spanning biostatistics, oncology, and infectious diseases, she contributes significantly to clinical research across multiple medical disciplines through rigorous statistical analysis and methodological innovation. Her educational background includes: MS in Medical Statistics from University of Rochester School of Medicine & Dentistry (2009) BS in Cell Biology, Cytology from University of Rochester (2008) BA in Statistics from University of Rochester (2008) Ms. Baran's research focuses on biostatistical methodology applied to clinical medicine , with particular emphasis on oncology, hematology, and infectious disease applications. Her work bridges statistical theory with clinical practice, developing analytical approaches for complex medical data including gene expression patterns, clinical trial outcomes, and disease progression models. She has made significant contributions to studies examining miRNA analysis, clinical trial design, and biomarker development. Analysis of her recent publication record reveals a strong concentration on hematologic malignancies, particularly chronic lymphocytic leukemia and lymphoma, where she applies sophisticated statistical models to evaluate treatment efficacy, resistance mechanisms, and patient outcomes. Her work also extends to infectious disease research, where she develops statistical approaches for understanding host immune responses to respiratory viruses and other pathogens. While specific awards are not mentioned in available records, her extensive publication history in high-impact journals including Journal of Infectious Diseases , Blood Advances , and Genome Biology demonstrates significant recognition within her fields of expertise. Ms. Baran collaborates extensively with clinical researchers across the University of Rochester Medical Center, providing biostatistical leadership for numerous clinical trials and observational studies. Her work supports research initiatives in oncology, hematology, infectious diseases, and geriatric care, contributing to evidence-based medical practice through rigorous statistical analysis and interpretation of complex datasets. She is actively involved in multiple research teams studying hematologic malignancies, infectious diseases, and clinical trial methodology, where her biostatistical expertise helps shape research design, data collection protocols, and interpretation of findings for clinical application.

Caroline Arber Barthمشاهده پروفایل

دانشیار

• Hematology
• Immuno-oncology
• Hematopoietic Cell Transplantation
• +۷ مورد دیگر

Caroline Arber Barth is an Associate Professor at the University of Lausanne (UNIL), affiliated with the Faculty of Biology and Medicine and the UNIL-CHUV Department of Oncology. She specializes in hematology and immuno-oncology, with a focus on hematopoietic cell transplantation and immunotherapy using genetically modified cells. Her research spans basic, translational, and clinical domains, aiming to improve cancer immunotherapies through adoptive T cell transfer and neoantigen identification. She has pioneered approaches to reduce post-transplant infections and enhance immune reconstitution. Her work targets long-term tumor control while minimizing toxicity in patients. The trends in her publications reflect a strong focus on cellular therapies, particularly CAR-T and TCR-modified T cells, for treating hematological malignancies such as leukemia, lymphoma, and myeloma. Her research integrates molecular engineering, tumor immunology, and clinical applications, emphasizing personalized treatment strategies. Awarded international recognition, her scientific honors include: Dean's Recognition, Stanford University (2002) L'Oréal UNESCO Award for Women in Science (2010) Award from the American Society of Bone Marrow Transplantation (2012) Award from the American Society of Hematology (2013) She has secured major research funding from the NIH, SNSF, Oncosuisse, the Leukemia and Lymphoma Society, and the Cancer Prevention and Research Institute of Texas. She has supervised multiple undergraduate and doctoral students and is actively involved in teaching at both Swiss and U.S. institutions. Her laboratory, based at the Center for Cellular and Gene Therapy (CAGT) during her time in Houston and now at UNIL-CHUV, focuses on developing next-generation cell therapies for cancer.

Adrian Smithمشاهده پروفایل

استاد

• Immunology
• Infectious Diseases
• Avian Biology
• +۵ مورد دیگر

Adrian Smith is a Professor of Zoology and Director of Graduate Studies (Progression) at the University of Oxford's Department of Zoology. His research focuses on the mechanisms of immunity to infectious diseases in vertebrates, particularly birds and mammals, with an emphasis on gut immunity and T lymphocyte biology. He leads the Infectious Disease and Comparative Immunology Section, investigating pathogens like Eimeria spp. and Salmonella enterica to develop immune interventions, including vaccines. Research Interests: His work spans comparative immunology, T cell subsets in protective immunity, and host-pathogen interactions. Current projects include pattern recognition receptors, γδ T cell biology, and parasite genetics for identifying protective antigens. He has pioneered reverse immunodynamics to identify protective immune targets. Scientific Awards: Recipient of the Daiwa Foundation Lord Adrian Prize (2007) for enteric T cell research and holds Jenner Investigator status for contributions to vaccine development. Advising & Grants: Supervises graduate students (e.g., Denise Wawman, Mirudula Elanchezhian) and collaborates with researchers like Dr. Divya Venkatesh (BBSRC Discovery Fellow). His lab integrates genomic, archaeological, and ecological approaches to understand immune evolution and pathogen dynamics in historical and modern populations. Labs/Teams: Active in the Smith & Bonsall Groups, focusing on avian immunology and pathogen biology. Collaborates across disciplines, including microbiome analysis, ancient DNA studies, and wildlife disease ecology.

Rachel O'Neillمشاهده پروفایل

استاد

• Genome Stability
• Retroelement Transcription
• Centromere Function
• +۵ مورد دیگر

Rachel O'Neill serves as a Board of Trustees Distinguished Professor in the Department of Molecular and Cell Biology at the University of Connecticut's College of Liberal Arts and Sciences. Her research bridges molecular genetics, cytogenetics, and computational genomics to investigate fundamental mechanisms of genome stability and evolution across diverse eukaryotic species. Her primary research interests focus on retroelement transcription, centromere function, chromosome evolution, and species-specific genomic adaptations. O'Neill's lab pioneers telomere-to-telomere (T2T) genome assembly methodologies using next-generation sequencing technologies, establishing non-traditional model organisms including marsupials, monotremes, birds, marine species, plants, and insects for comparative genome biology studies. Human Telomere-to-Telomere Consortium Primate T2T Consortium Gibbon T2T Consortium Earth Biogenomes Project Ruminant T2T Consortium Fly T2T Consortium Deep Ocean Genomes Project Antarctic Genomes Consortium Colossal Foundation UConn’s Biodiversity and Conservation Genomics program O'Neill's recent publications (2021-2025) demonstrate leadership in large-scale genomics initiatives, with significant contributions to understanding centromere biology, sex chromosome evolution, and conservation genomics. Her work spans marsupial mole genomics, ruminant chromosome evolution, and epigenetic regulation of X-chromosome inactivation, reflecting her lab's broad impact across evolutionary biology, conservation, and fundamental genome science. Her laboratory actively trains students through cohort-based programs including the RaMP Cohort and Biodiversity and Conservation Genomics Program, securing substantial collaborative funding through multi-institutional consortia. The lab maintains strong infrastructure for advanced genome assembly and epigenomic analysis, with particular expertise in challenging repetitive regions and non-model organism genomics.

Danika Hillمشاهده پروفایل

پژوهشگر ارشد

• Immunology
• Vaccine Development
• Cellular and Molecular Mechanisms of Immunity
• +۵ مورد دیگر

Danika Hill is a Senior Research Fellow in the Department of Immunology and Pathology at Monash University. Her research focuses on understanding cellular and molecular mechanisms of immune responses to vaccination and infection, particularly in T follicular helper cells and germinal center biology. She investigates pathogens such as Group A Streptococcus, malaria, and influenza using advanced techniques like high-parameter flow cytometry and single-cell sequencing. Education: BSc in Biomedical Science (University of Adelaide), PhD (Walter and Eliza Hall Institute). Postdoctoral training at the Babraham Institute (Cambridge) before joining Monash in 2020. Funded by NHMRC CJ Martin Fellowship and Michelson Prize. Recognized as a 'Rising Star in Immunology' by the Norwegian Society for Immunology. Research Interests T follicular helper cell dynamics and germinal center regulation Long-lived antibody responses and vaccine design Age-related immune dysfunction Immune responses to infectious diseases Awards Michelson Prize (2020) Margaret Baird Women in Immunology Award (2022) NHMRC CJ Martin Fellowship (2018) Best Oral presentation awards (2020, 2022) Grants & Projects "Discovering molecular signatures of human T follicular helper cells and antibody-producing B cells" (NHMRC, 2018–2023) "Structure-based antigen design for mRNA vaccines" (2023–2025) Labs/Teams: Leads her own lab at Monash, collaborating internationally on vaccine efficacy and immune mechanisms.

• Cancer Immunotherapy
• Gastrointestinal Oncology
• Immunotherapy Resistance Mechanisms
• +۵ مورد دیگر

Bridget Keenan, MD, PhD is an Assistant Professor in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine. She serves as Co-Director of the Cancer Immunotherapy Program and Medical Director of the Cancer Immunotherapy Clinic at UCSF. Dr. Keenan completed her MD and PhD at Johns Hopkins University School of Medicine in 2015, focusing on cancer vaccines to overcome immune suppression in pancreatic cancer mouse models. She completed her Internal Medicine residency at UCSF in 2017 and her Hematology/Oncology fellowship at UCSF with training in gastrointestinal oncology and cancer immunotherapy. In 2022, she completed UCSF's Diversity, Equity, and Inclusion Champion Training. Her research focuses on mechanisms of response and resistance to immunotherapy, particularly in gastrointestinal cancers. She clinically sees patients with solid tumor malignancies receiving cutting-edge immunotherapies including cell therapies and T cell engagers. Her work spans both basic science investigations of tumor microenvironment dynamics and clinical trials of novel immunotherapeutic approaches. Analysis of her recent publications (2023-2025) reveals a strong emphasis on gastrointestinal cancer immunotherapy, particularly CAR T-cell therapies for colorectal cancer, CD40 agonists for esophageal cancer, and mechanisms of immunotherapy resistance. She has significant contributions in biomarker development (including neutrophil-to-lymphocyte ratios) and has recently expanded her research to include gender equity in academic medicine. Co-Director, Cancer Immunotherapy Program Medical Director, Cancer Immunotherapy Clinic Principal Investigator on multiple phase I/II clinical trials for novel immunotherapies Active participant in UCSF's Diversity, Equity, and Inclusion initiatives Dr. Keenan's collaborative work spans numerous institutions and involves close partnerships with leading researchers in oncology, immunology, and bioinformatics. Her recent publications demonstrate growing leadership in both clinical immunotherapy trials and research addressing structural issues in academic medicine.

Torsten Nielsenمشاهده پروفایل

استاد

• Sarcoma
• Breast Cancer
• Molecular Diagnostics
• +۷ مورد دیگر

Professor Torsten Nielsen is a clinician-scientist at the University of British Columbia 's Department of Pathology & Laboratory Medicine (Faculty of Medicine), based at Vancouver General Hospital and BC Cancer . He directs UBC's MD/PhD Program , contributes to cancer clinical trials with the Canadian Cancer Trials Group , and chairs the international Connective Tissue Oncology Society 's Research Committee. Key affiliations: UBC, Vancouver General Hospital, BC Cancer, Molecular and Advanced Pathology Core Academic focus: Translational research in sarcomas and breast cancer His research prioritizes translating genomic discoveries into clinical diagnostics and treatments, particularly for synovial sarcoma , breast cancer subtypes , and tenosynovial giant cell tumors . He develops FDA-cleared molecular assays like the PAM50 (Prosigna) test and leads pan-Canadian precision oncology initiatives . Collaborative efforts include work with Stanford, Leiden, and DKFZ Heidelberg. Recent publications highlight advancements in epigenetic therapies , immune biomarker validation , and synovial sarcoma pathogenesis . His lab's work on CSF1/CSF1R signaling inspired new treatment strategies for joint-destructive tumors. Scientific Awards: Fellow, Canadian Academy of Health Sciences Fellow, Royal Society of Canada As director of UBC's MD/PhD Program, he trains future clinician-scientists. His lab team includes experts in epigenomics , proteomics , and mouse modeling . Current projects focus on precision oncology for sarcomas and Ki67 standardization in breast cancer.

• Oncology
• Digital Pathology
• Machine Learning in Healthcare
• +۳ مورد دیگر

Yalai Bai is a Research Scientist and Technical Director of Tissue Distribution and Analysis Service in the Pathology Department at Yale School of Medicine. She holds a PhD and MD from Peking University Health Science Center (1996 and 1990, respectively). Her research focuses on quantitative biomarker analysis, tumor immunology, and machine learning applications in pathology. Key projects include developing automated algorithms for tumor-infiltrating lymphocyte (TIL) scoring and standardizing Ki67 and HER2 expression measurements. She collaborates internationally on clinical trials, such as the EORTC 10994/BIG 1-00 breast cancer trial, and contributes to translational studies on cancer metastasis and therapeutic response prediction. Education : PhD in Pathology, Peking University Health Science Center (1996) MD, Peking University Health Science Center (1990) Labs/Teams : Rimm Lab (specializing in quantitative pathology and computational oncology) Tissue Procurement & Distribution team (supporting large-scale clinical studies) Her work bridges clinical pathology and computational methods, addressing challenges in reproducibility and standardization. Recent studies highlight spatial tumor-immune microenvironment analysis and AI-driven biomarker validation across breast, head & neck, and gynecologic cancers. Contributions also include optimizing pre-analytic variables for antigen stability and advancing open-source tools for TIL quantification in triple-negative breast cancer.